JP2021500891A - 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス - Google Patents

卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス Download PDF

Info

Publication number
JP2021500891A
JP2021500891A JP2020523276A JP2020523276A JP2021500891A JP 2021500891 A JP2021500891 A JP 2021500891A JP 2020523276 A JP2020523276 A JP 2020523276A JP 2020523276 A JP2020523276 A JP 2020523276A JP 2021500891 A JP2021500891 A JP 2021500891A
Authority
JP
Japan
Prior art keywords
residue
influenza virus
virus
encode
isolated recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020523276A
Other languages
English (en)
Japanese (ja)
Inventor
河岡 義裕
義裕 河岡
晋弥 山田
晋弥 山田
志穂 千葉
志穂 千葉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Tokyo
Original Assignee
The University of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Tokyo filed Critical The University of Tokyo
Publication of JP2021500891A publication Critical patent/JP2021500891A/ja
Priority to JP2022144599A priority Critical patent/JP7575012B2/ja
Priority to JP2024176620A priority patent/JP2024177515A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020523276A 2017-10-25 2018-10-25 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス Pending JP2021500891A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022144599A JP7575012B2 (ja) 2017-10-25 2022-09-12 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス
JP2024176620A JP2024177515A (ja) 2017-10-25 2024-10-08 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762577049P 2017-10-25 2017-10-25
US62/577,049 2017-10-25
US201862633400P 2018-02-21 2018-02-21
US62/633,400 2018-02-21
PCT/US2018/057576 WO2019084310A1 (en) 2017-10-25 2018-10-25 HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144599A Division JP7575012B2 (ja) 2017-10-25 2022-09-12 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス

Publications (1)

Publication Number Publication Date
JP2021500891A true JP2021500891A (ja) 2021-01-14

Family

ID=64270970

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523276A Pending JP2021500891A (ja) 2017-10-25 2018-10-25 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス
JP2022144599A Active JP7575012B2 (ja) 2017-10-25 2022-09-12 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス
JP2024176620A Pending JP2024177515A (ja) 2017-10-25 2024-10-08 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022144599A Active JP7575012B2 (ja) 2017-10-25 2022-09-12 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス
JP2024176620A Pending JP2024177515A (ja) 2017-10-25 2024-10-08 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス

Country Status (4)

Country Link
US (3) US11197926B2 (cg-RX-API-DMAC7.html)
EP (1) EP3700562A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021500891A (cg-RX-API-DMAC7.html)
WO (1) WO2019084310A1 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11802273B2 (en) 2014-06-20 2023-10-31 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US12122807B2 (en) 2019-05-01 2024-10-22 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12410409B2 (en) 2011-08-26 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980060A4 (en) 2019-06-07 2023-04-12 Flugen, Inc. FLU VIRUS BACKBONE
WO2021178621A1 (en) * 2020-03-06 2021-09-10 University Of Washington Engineered influenza neuraminidase antigens
WO2022020469A1 (en) 2020-07-21 2022-01-27 Flugen, Inc. Influenza virus backbone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523252A (ja) * 2007-04-16 2009-06-18 ビ−エイイ− システムズ パブリック リミテッド カンパニ− 腐食センサ
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
JP2013507990A (ja) * 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
JP2016500007A (ja) * 2012-11-16 2016-01-07 メディミューン,エルエルシー ブタインフルエンザヘマグルチニン及びノイラミニダーゼ変異体
JP2016524915A (ja) * 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2016207853A2 (en) * 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017143236A1 (en) * 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927290B1 (cg-RX-API-DMAC7.html) 1969-08-05 1974-07-16
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
JP3484215B2 (ja) 1994-01-27 2004-01-06 花王株式会社 チャイニーズハムスター卵巣細胞変異株
US5750394A (en) 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
CA2149197A1 (en) 1994-06-17 1995-12-18 Irene Popiel Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
EP0700991A1 (en) 1994-09-12 1996-03-13 Bayer Corporation Commercial scale concentrated preharvest tissue culture produced live T. Gondii bradyzoite and products and processes
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
EP0704533A1 (en) 1994-09-30 1996-04-03 Bayer Ag An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US6843996B1 (en) 1995-06-05 2005-01-18 Medimmune Vaccines, Inc. Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US5994526A (en) 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6271011B1 (en) 1996-10-15 2001-08-07 The University Of Georgia Research Foundation, Inc. Pasteurella neuraminidase coding sequences and diagnostic methods
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998048834A1 (en) 1997-04-30 1998-11-05 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
EP0996717B1 (en) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoprotective influenza antigen and its use in vaccination
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US20020010143A1 (en) 1997-09-26 2002-01-24 Miguel S. Barbosa Compositions and methods for the treatment of human cytomegalovirus infection
KR100281676B1 (ko) 1997-11-29 2001-04-02 신동권 신규한독감생백신바이러스
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6270958B1 (en) 1998-10-29 2001-08-07 Washington University Detection of negative-strand RNA viruses
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
DK1820853T3 (da) 1999-04-06 2011-12-19 Wisconsin Alumni Res Found Rekombinant influenzavirus til vacciner og genterapi
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AU7841400A (en) 1999-10-01 2001-05-10 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
AU782624B2 (en) 1999-12-30 2005-08-18 Board Of Trustees Of Miami University Methods and compositions for inhibiting adhesion by microorganisms
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
AU5921101A (en) 2000-04-28 2001-11-12 St Jude Childrens Res Hospital Dna transfection system for the generation of infectious influenza virus
US6358733B1 (en) 2000-05-19 2002-03-19 Apolife, Inc. Expression of heterologous multi-domain proteins in yeast
US20040241139A1 (en) 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
EP1201760A1 (en) 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
US7449188B2 (en) 2001-01-18 2008-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Recombinant oligometric protein complexes with enhanced immunogenic potential
EP1233059A1 (en) 2001-02-09 2002-08-21 ARTEMIS Pharmaceuticals GmbH Influenza viruses with enhanced transcriptional and replicational capacities
EP1364006A2 (en) 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
CA2465895C (en) 2001-11-07 2012-10-02 U.S. Army Medical Research Institute Of Infectious Diseases Department Of The Army Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding
US7682618B2 (en) 2001-11-07 2010-03-23 The United States Of America As Represented By The Secretary Of The Army Generation of virus-like particles and use as panfilovirus vaccine
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
CN1997734A (zh) 2002-02-13 2007-07-11 威斯康星旧生研究基金会 包装流感病毒载体的信号
EP3009507B1 (en) 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
WO2003076462A1 (en) 2002-03-08 2003-09-18 Crucell Holland B.V. Use of recombinant trypsin for vaccine production
FR2837497A1 (fr) 2002-03-22 2003-09-26 Univ Nantes Procede de production de vecteurs lentiviraux a haut titre
CN1678345B (zh) 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20060088909A1 (en) 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
DK1520008T3 (da) 2002-07-09 2012-10-15 Baxter Int Medium frit for dyreprotein til dyrkning af celler
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20040142322A1 (en) 2002-10-07 2004-07-22 Schering Corporation Continuous non-radioactive polymerase assay
JP2007525175A (ja) 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
AU2004274860A1 (en) 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
ES2593082T3 (es) 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060240515A1 (en) 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US7279275B2 (en) 2003-11-03 2007-10-09 Washington University Methods and compositions for detection of segmented negative strand RNA viruses
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
JP2005245302A (ja) 2004-03-04 2005-09-15 Kanazawa Univ Tlo Inc 組換えインフルエンザウイルスおよびそれを用いたワクチン
US20060099609A1 (en) 2004-04-13 2006-05-11 Sina Bavari Activation of natural killer (NK) cells and methods of use
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
KR20070100882A (ko) 2004-11-11 2007-10-12 솔베이 파마슈티칼스 비. 브이 결손 인플루엔자 바이러스 입자
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
NZ556061A (en) 2004-12-24 2009-06-26 Solvay Biologicals Bv Rescue of influenza virus
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
KR20080052509A (ko) 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
FR2887958B1 (fr) 2005-07-01 2007-10-12 Prospection Et D Inv S Techniq Dispositif de reglage de commande de vanne pour appareil de fixation a gaz et l'appareil comportant le dispositif
NL1030161C2 (nl) 2005-10-11 2007-04-12 Matthijs Dirk Meulenbelt Presentatie-inrichting.
ES2402061T3 (es) 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
AU2012204138B2 (en) 2006-03-31 2014-02-06 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2014202470B2 (en) 2006-03-31 2016-08-04 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
EP2022849A4 (en) 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst PROCESS FOR THE PROLIFERATION OF INFLUENZA VIRUS
US20090017444A1 (en) 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CA2659267C (en) 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
US8465960B2 (en) 2007-03-28 2013-06-18 Wisconsin Alumni Research Foundation Influenza B viruses with reduced sensitivity to neuraminidase inhibitors
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US8043856B2 (en) 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
WO2008155681A1 (en) 2007-06-21 2008-12-24 Nds Limited Power saving device
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
WO2009014919A2 (en) 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
WO2009128867A2 (en) 2008-01-07 2009-10-22 Warf - Wisconsin Alumni Research Foundation Recombinant biologically contained filovirus
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
US8591914B2 (en) 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン,インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010053573A2 (en) 2008-11-07 2010-05-14 Yoshihiro Kawaoka Screen for inhibitors of filovirus and uses therefor
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
US8507247B2 (en) 2009-08-11 2013-08-13 Wisconsin Alumni Research Foundation Influenza A virus with attenuating mutations in NS2 protein
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101740019B1 (ko) 2009-11-10 2017-05-26 주식회사 팬택 무선통신시스템에서 시스템 정보 송수신 방법 및 그를 이용한 시스템 정보 송신장치와 수신장치
AU2010321710B2 (en) 2009-11-23 2013-03-07 Wm. Wrigley Jr. Company Gum bases, chewing gums based thereupon, and methods for making the same
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130034578A1 (en) 2010-04-09 2013-02-07 Petrus Josephus Marie Rottier Recombinant multimeric influenza proteins
WO2011130627A2 (en) 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012033236A1 (ko) 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
MX2013006234A (es) 2011-01-06 2013-08-01 Univ Johns Hopkins Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
CN106995802B (zh) 2011-06-24 2021-04-09 复尔健有限公司 流感病毒突变体及其用途
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
CN102304495A (zh) 2011-09-08 2012-01-04 中国农业科学院上海兽医研究所 高效表达ha蛋白的重组流感病毒及其制备方法和应用
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたrnaの新規の送達
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
SG10201807208RA (en) 2014-03-04 2018-09-27 Sigma Aldrich Co Llc Viral resistant cells and uses thereof
US9757446B2 (en) 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CA2959105C (en) 2014-09-03 2023-10-17 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10429386B2 (en) 2015-03-10 2019-10-01 The Regents Of The University Of California Antibodies to the surface of Toxoplasma gondii oocysts and methods of use thereof
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US20170121391A1 (en) 2015-07-07 2017-05-04 Wisconsin Alumni Research Foundation (Warf) Potent glycoprotein antibody as a therapeutic against ebola virus
WO2017040203A1 (en) 2015-08-28 2017-03-09 Yoshihiro Kawaoka Generation of infectious influenza viruses from virus-like particles
CN105296356A (zh) 2015-12-02 2016-02-03 河南农业大学 一种刚地弓形虫卵囊的制备、纯化及保存方法
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
JP2018064493A (ja) 2016-10-19 2018-04-26 京都府公立大学法人 Mdck細胞を用いたインフルエンザウイルスの増殖方法
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
WO2019241579A1 (en) 2018-06-13 2019-12-19 Wisconsin Alumni Research Foundation Toxoplasma gondii vaccine
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12064478B2 (en) 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US20220249652A1 (en) 2019-06-26 2022-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus neuraminidase and uses thereof
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたnaを有する組換えインフルエンザウイルス
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2021242597A1 (en) 2020-05-23 2021-12-02 Wisconsin Alumni Research Foundation ("Warf") Ace2 expressing influenza virus
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
US20230321217A1 (en) 2021-09-28 2023-10-12 Yoshihiro Kawaoka Compositions comprising complexes displaying antigens and methods of using the compositions
WO2023125889A1 (en) 2021-12-31 2023-07-06 Suzhou Abogen Biosciences Co., Ltd. Quadrivalent mrna vaccines for influenza viruses
WO2023164556A2 (en) 2022-02-23 2023-08-31 Wisconsin Alumni Research Foundation Broadly protective influenza b virus vaccines
WO2024015510A1 (en) 2022-07-13 2024-01-18 Wisconsin Alumni Research Foundation ("Warf") Sars-cov-2 lacking the envelope protein as an attenuated vaccine virus against covid-19
US20240238403A1 (en) 2022-11-16 2024-07-18 Wisconsin Alumni Research Foundation Influenza virus replication for vaccine development
US20260226425A1 (en) 2023-03-21 2026-08-06 The University Of Tokyo Cold-adapted, live attenuated sars-cov-2 vaccine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523252A (ja) * 2007-04-16 2009-06-18 ビ−エイイ− システムズ パブリック リミテッド カンパニ− 腐食センサ
JP2013507990A (ja) * 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
JP2016500007A (ja) * 2012-11-16 2016-01-07 メディミューン,エルエルシー ブタインフルエンザヘマグルチニン及びノイラミニダーゼ変異体
JP2016524915A (ja) * 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2016207853A2 (en) * 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017143236A1 (en) * 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. VIROL., 2007, VOL.81, NO.22, PP.12418-12426, JPN6021028714, ISSN: 0004556781 *
J. VIROL., 2013, VOL.87, NO.8, PP.4642-4649, JPN6021028713, ISSN: 0004556782 *
PLOS ONE, 2013, VOL.8, ISSUE 6, E65955 (PP.1-16), JPN6021028715, ISSN: 0004556780 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US12410409B2 (en) 2011-08-26 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
US11802273B2 (en) 2014-06-20 2023-10-31 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12258557B2 (en) 2019-02-08 2025-03-25 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12122807B2 (en) 2019-05-01 2024-10-22 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Also Published As

Publication number Publication date
JP2024177515A (ja) 2024-12-19
US20190167781A1 (en) 2019-06-06
EP3700562A1 (en) 2020-09-02
US12251436B2 (en) 2025-03-18
JP7575012B2 (ja) 2024-10-29
US11197926B2 (en) 2021-12-14
US20220202927A1 (en) 2022-06-30
WO2019084310A1 (en) 2019-05-02
JP2022172369A (ja) 2022-11-15
US20250255953A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
JP7575012B2 (ja) 卵における複製のための安定化されたhaを有する組換えインフルエンザウイルス
US12365880B2 (en) Recombinant influenza viruses with stabilized NA
JP7691380B2 (ja) Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10808229B2 (en) High titer recombinant influenza viruses with enhanced replication in vero cells
US12122807B2 (en) Influenza virus replication for vaccine development
US10246686B2 (en) Influenza virus replication for vaccine development
US20240076632A1 (en) Recombinant influenza viruses with stabilized ha for replication in eggs
US10633422B2 (en) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510